adimin

FDA approves new treatment for rare liver disorder

FOSTER CITY, Calif. - The U.S. Food and Drug Administration (FDA) has approved LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients aged five years and older with progressive familial intrahepatic cholestasis (PFIC), Mirum Pharmaceuticals (NASDAQ:MIRM) announced today. The approval, based on the Phase 3 MARCH study, signifies a statistically significant reduction...

Read More